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Abstract. Currently, sorafenib is the only available chemo-
therapeutic agent for advanced hepatocellular carcinoma 
(HCC), but it cannot be used in patients with liver cirrhosis 
(LC) or thrombocytopenia. In these cases, sorafenib is likely 
effective if given in combination with treatments that increase 
the number of platelets, such as thrombopoietin (TPO) 
receptor agonists. Increasing the platelet count via TPO treat-
ment resulted in reduction of LC. Eltrombopag (EP), a TPO 
receptor agonist, has been reported to have antitumor effects 
against certain cancers, despite their lack of TPO receptor 
expression. We hypothesized that EP may possess antitumor 
activity against HCC in addition to its ability to suppress 
hepatic fibrosis by increasing the platelet count. In the present 
study, the antitumor activity of EP was examined by assessing 
the inhibition of cell proliferation and then ascertaining the 
ability of iron supplementation to reverse these effects in 
HepG2, Hep3B and Huh7 cells. In addition, a cell cycle assay 
was performed using flow cytometry, and signal transduc-
tion was evaluated by analyzing cell cycle-related protein 
expression. The results of EP were compared with those of 
the most common iron chelator, deferoxamine (DFO). The 
combined effect of EP and sorafenib was also assessed. The 
results revealed that EP exerts antitumor activity in HCC that 
is mediated by the modulation of intracellular iron content. 
EP suppressed the expression of the cell cycle-related protein 
cyclin D1 and elicited cell cycle arrest in the G0/G1 phase. 
The activity of EP was comparable to that of DFO in HCC, 
and EP did not compete with sorafenib at low concentrations. 
In conclusion, our findings suggest that EP is a good candidate 
chemotherapeutic agent for the treatment of HCC in patients 
with LC and thrombocytopenia.
Introduction
Hepatocellular carcinoma (HCC) is the most common disease 
that causes primary liver tumors and the fifth most common 
malignant disease in the world (1). HCC develops frequently in 
patients with liver cirrhosis (LC) (2). HCC has a poor prognosis 
and a high rate of recurrence, even after treatment. Currently, 
sorafenib is the only available chemotherapeutic agent for 
advanced HCC, but it cannot be used to treat patients with 
LC and thrombocytopenia due to the risk of bleeding (3-5). 
Therefore, there is an urgent need for the development of 
effective therapeutic agents for HCC.
Thrombopoietin (TPO) is the most important growth 
factor in the regulation of megakaryocyte development and 
platelet production (6). TPO is the endogenous ligand of the 
TPO receptor [(TPO-R, also known as myeloproliferative 
leukemia virus oncogene (MPL)], which is expressed on the 
surface of megakaryocytes, megakaryocyte precursors and 
platelets (7-10).
Eltrombopag (EP) is an oral, nonpeptide, small molecule 
TPO-R agonist that has proven efficacy in treating chronic 
immune thrombocytopenic purpura (ITP) and hepa-
titis C-related thrombocytopenia (11,12).
Despite concerns that some leukemia blast cells express 
TPO-R, EP has been reported to have no proliferative effects 
in patients with myelodysplastic syndromes or AML (13); 
instead, EP inhibits the proliferation of leukemia cell 
lines (14).
Additionally, recent studies have demonstrated that 
the antileukemic effect of EP is not related to the TPO-R 
pathway (15) and that EP inhibits the growth of breast, lung, 
and ovarian tumor cells (16). EP has been reported to increase 
platelet counts in a short-term clinical study that included 
patients with HCC (17). However, it remains unclear whether 
EP has an antitumor effect in HCC.
The purpose of this study was to clarify whether EP affects 
the growth of human HCC cells in vitro.
Materials and methods
Reagents. EP (SB-497115; Selleck Chemicals, Houston, TX, 
USA) was dissolved as a 1 mg/ml stock solution in distilled 
water and was stored in the dark at room temperature for 
up to 2 weeks. Deferoxamine mesylate (DFO) and ferrous 
ammonium citrate (FAC) were purchased from Sigma-Aldrich 
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(St. Louis, MO, USA), and sorafenib was purchased from 
Invitrogen (Grand Island, NY, USA).
Cell culture. Human hepatoblastoma cell lines (HepG2 and 
Hep3B) and a well-differentiated human HCC cell line (Huh7) 
were used in these experiments. HepG2, Hep3B and Huh7 
cells were cultured in Dulbecco's modified Eagle's medium 
(DMEM; Wako Pure Chemical Industries, Ltd., Osaka, 
Japan) supplemented with 10% fetal bovine serum (FBS; 
HyClone, Logan, UT, USA) and 1% penicillin/streptomycin 
(Invitrogen).
Cell proliferation. Following cell incubation at 37˚C for 24 h, 
the medium was changed to 100 µl of DMEM supplemented 
with 10% FBS, and different concentrations (0.1, 0.4, 1, 4, 10, 
40 and 100 µg/ml) of EP were added to each well. A recent 
double-blind, placebo-controlled, randomized dose-escalation 
study showed that maximum EP serum concentrations of 
>20 µg/ml are clinically achievable with minimal toxicity (18). 
The reported IC50 values of EP in other cancer cell lines range 
from 4.8 to 49.7 µg/ml (16). Additionally, 0.4 µg/ml EP is 
equivalent to 1 µM of EP. Therefore, we selected the concen-
trations indicated above. After a 72-h incubation at 37˚C, the 
cells were counted based on DNA content using a bromode-
oxyuridine (BrdU) assay kit (Roche Diagnostics, Penzberg, 
Germany) and Cell Counting Kit-8 (CCK-8) (Dojindo 
Laboratories, Kumamoto, Japan) according to the instructions 
of the manufacturers.
The mechanism by which EP inhibits HCC cell growth 
has not been well characterized. EP reduces intracellular iron 
concentrations, and iron chelators exhibit anti-proliferative 
effects in myeloid leukemia cells (15). We investigated whether 
the antitumor effect of EP is secondary to its ability to deplete 
intracellular iron. Iron was pre-loaded into cells by treatment 
with 500 µg/ml FAC for 24 h prior to EP addition.
Cell cycle analysis. Changes in the cell cycle after EP treat-
ment were assessed using a Muse™ cell cycle kit (EMD 
Millipore, Billerica, MA, USA). The cells were cultured in 
10-cm dishes with various concentrations of EP (0-100 µg/ml) 
for 72 h. After treatment, the cells were collected in DMEM 
supplemented with 1% FBS, and the Muse™ cell cycle test 
reagent was added. The cells were mixed by vortexing, and the 
reaction was allowed to proceed for 30 min at room tempera-
ture in the dark. Then, the cells were stained to determine the 
proportions of cells in the G0/G1, S and G2/M phases using a 
Muse™ cell analyzer (EMD Millipore).
Western blot analysis of transcription factors. Huh7 cells 
and hepatocytes were pre-cultured separately in 6-well plates 
for 24 h; subsequently, the medium was changed to DMEM 
supplemented with 10% FBS, and 0-100 µg/ml EP was added 
to each well. Cells were harvested 72 h after the addition 
of EP. For the western blot analysis, the cell lysates were 
subjected to 10% sodium dodecyl sulfate-polyacrylamide 
gel electrophoresis (SDS-PAGE) and transferred to a 
nitrocellulose membrane (EMD Millipore). The membranes 
were exposed to primary antibodies against cyclin-dependent 
kinase inhibitor 1A (p21/CDKN1A) and the G1/S-specific 
protein cyclin D1 (CCND1). Glyceraldehyde 3-phosphate 
dehydrogenase (GAPDH; Cell Signaling Technology, Inc., 
Beverly, MA, USA) was used as an endogenous control. An 
anti-rabbit immunoglobulin G horseradish peroxidase-linked 
secondary antibody was used (Cell Signaling Technology, 
Inc.).
The most common iron chelator: DFO. To compare the effects 
of DFO, with those of EP, Huh7 cells were treated with DFO 
(0.1-100 µg/ml) for 72 h, or not treated. Cell viability was 
measured at 72 h using a CCK-8 assay as described above.
Evaluation of the combined effects of EP and sorafenib. Huh7 
cells were exposed to combinations of EP (0-40 µg/ml) and 
sorafenib (4 µM) for 72 h. The effect on cell proliferation was 
assessed using the CCK-8 assay, and the rate of growth inhibi-
tion was calculated using the combination index (CI) according 
to the method reported by Chou (19). The CI was obtained 
using Biosoft CalcuSyn software (Biosoft, Cambridge, UK): 
CI=1, cumulative effect; CI<1, synergistic effect; and CI>1, 
antagonistic effect.
Statistical analysis. The data are presented as the mean and 
standard deviation. Statistical analyses were performed using 
the Mann-Whitney U test or one-way ANOVA, and significant 
results were analyzed using the Bonferroni-Dunn multiple 
comparisons post hoc test. In all cases, P<0.05 was considered 
significant.
Results
Effect of EP on human HCC cell lines. HCC cells were treated 
with various doses of EP for 72 h, and cell viability was 
assessed using the BrdU assay (Fig. 1A-C). As the dose of EP 
increased from 0.1 to 100 µg/ml, cell growth was inhibited in 
a dose-dependent manner in Huh7, HepG2 and Hep3B cells. 
Compared with the non-treated cells, EP significantly inhib-
ited cell proliferation at concentrations of 40-100 µg/ml based 
on the BrdU assay results.
Preloading HCC cell lines with iron diminishes the 
anti-proliferative effects of EP. Huh7, HepG2 and Hep3B cells 
were preloaded with iron (500 µg/ml FAC) for 24 h before 
EP addition to clarify the antitumor mechanism of action of 
EP. CCK-8 cell proliferation assays were performed after 72 h. 
The IC50 values of EP in the HCC cell lines were 5.7 µg/ml 
for Huh7, 5.4 µg/ml for HepG2, and 4.7 µg/ml for Hep3B. 
Iron-loaded Huh7 cells were non-treated (control), or treated 
with EP. Preloading Huh7 cells with iron nearly abolished the 
anti-proliferative effects of EP (Fig. 2A-C).
EP elicited G1 arrest in a human HCC cell line. Huh7 cells 
were treated with EP (0 or 10 µg/ml) for 72 h, and the cells 
were monitored during the transition from the G0/G1 phase 
to S phase. Treatment with 10 µg/ml EP significantly 
induced G0/G1 phase arrest compared with control treat-
ment (Fig. 3A).
Effects of EP on cell cycle-related protein expression in an 
HCC cell line. Treatment with iron chelators significantly 
decreases CCND1 levels in various cancer cell types (20). 
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Therefore, we measured the protein levels of CCND1 and 
p21/CDKN1A using western blot analysis. Treatment with 
EP (0, 1, or 10 µg/ml) for 72 h downregulated the protein 
levels of CCND1 and p21/CDKN1A in a dose-dependent 
manner (Fig. 3B).
Comparison of the antitumor effects of DFO and EP. Huh7 
cells were treated with various doses of DFO for 72 h, and 
cell viability was analyzed using the CCK-8 assay. Cell prolif-
eration was inhibited in a dose-dependent manner in Huh7 
cells treated with DFO (0-100 µg/ml) (Fig. 4). EP was nearly 
equivalent to the most common iron chelator DFO, in terms of 
the inhibition of cell proliferation.
Combined effect of sorafenib and EP on HCC cells. Compared 
with untreated cells, EP (4-100 µg/ml) significantly inhib-
ited Huh7 cell proliferation in a dose-dependent manner, as 
evidenced by the CCK-8 assay results, in the presence of the 
antitumor agent 4 µM of sorafenib (Fig. 5A). The CI values 
were ~1 at 0.1-10 µg/ml EP (Fig. 5B). EP clearly did not 
antagonize sorafenib.
Discussion
Patients with advanced HCC and LC often present with 
thrombocytopenia. Therefore, it is difficult to use sorafenib, 
which currently is the only recognized effective treatment for 
advanced HCC (4).
EP, a second-generation TPO-R agonist that has the ability 
to increase platelet count, has been reported to have antitumor 
effects in several types of cancer (16).
The purpose of our study was to clarify the effects of EP 
on the growth of human HCC cells.
Figure 1. Effect of eltrombopag (EP) on human HCC cell lines. Cell lines were treated with 0-100 µg/ml EP. The inhibited cell proliferation rates are shown 
for (A) Huh7, (B) HepG2 and (C) Hep3B, respectively. *P<0.05 compared to 0 µg/ml EP. The values indicate ratio compared to 0 µg/ml EP as 100% control.
Figure 2. Preloading cells with iron resulted in a rescue from the antiproliferative effects of eltrombopag. Huh7 cells were untreated or treated with 
0.1-100 µg/ml of EP 72 h preloaded or not with 500 µg/ml of ferric ammonium citrate (FAC) for 24 h. Cell viability was measured with a CCK-8 assay per-
formed at 72 h. Comparison with the data without iron preloading. (A) Huh7, (B) HepG2 and (C) Hep3B. *P<0.05 compared to each dose EP not preloaded 
of FAC. The values indicate a ratio compared to 0 µg/ml EP as 100% control.
Figure 3. Effect of eltrombopag on cell cycle progression in Huh7 cells. 
(A) Cells were treated with EP (0 and 10 µg/ml) for 72 h. DNA was stained 
with propidium iodide, and flow cytometric analysis of cell phase distribution 
was performed using a Muse™ cell analyzer. (B) Cells were treated with EP 
(0, 1 and 10 µg/ml) for 72 h. Protein expression was determined by western 
blot analysis using anti-cyclin D1, anti-p21 and anti-GAPDH antibodies. 
SDS-PAGE was performed on acrylamide gels.
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In the present study, EP exhibited strong antitumor activity 
in HCC by eliciting cell cycle arrest through iron chelation 
rather than through TPO-R. We concluded that EP represents 
a novel treatment for HCC.
TPO-R, also known as myeloproliferative leukemia virus 
oncogene (MPL), has been reported to be expressed in liver 
sinusoidal endothelial cells (LSEC) in mice and in liver 
progenitor cells in rats, and TPO promotes the proliferation of 
both of these cell types (21,22).
However, we have already reported that TPO has no prolif-
erative effect on HCC in vitro or in vivo (23).
In contrast to TPO, the second-generation small molecule 
TPO-R agonist EP does not induce the production of neutral-
izing antibodies (24-28).
Recent studies have demonstrated that EP inhibits leukemia 
cell growth by depleting intracellular iron (15) and inhibits the 
growth of breast, lung and ovarian tumor cells (16).
These findings of tumor cell growth inhibition by EP 
in vitro and in vivo demonstrate that these effects of EP are 
TPO-R-independent.
The reported IC50 values of EP in various cell lines 
are 9.6-19.0 µg/ml for breast, 3.7-10.3 µg/ml for lung, and 
4.8-49.7 µg/ml for ovarian cancer. These results in our study 
supported the previous studies that indicated IC50 of EP in 
tumor cells.
The observed median Cmax for EP in patients with ITP is 
11.4 µg/ml at a 75-mg dose (29). The efficacy of EP in hepa-
titis C virus-infected patients with thrombocytopenia before 
the initiation of pegylated interferon and ribavirin therapy has 
been reported (12). A recent double-blind, placebo-controlled, 
randomized dose-escalation study showed that maximum 
serum concentrations of EP of >20 µg/ml are clinically achiev-
able with minimal toxicity (18).
EP has three primary features: a lipophilic end, an acidic 
end, and a chelator backbone (30,31). These elements enable 
EP to reduce intracellular iron as well as possibly other poly-
valent cations (24,32).
Iron (Fe) is a metal that is vital for the sustenance of 
life (33-35). It is an essential component of many proteins 
and enzymes that are involved in cell growth and replica-
tion (33,35). Cellular Fe depletion typically results in G1/S 
arrest (36,37), which indicates that this metal is essential 
for cell cycle progression as well as cell growth and divi-
sion (38,39).
Compared with normal cells, neoplastic cells require a 
greater amount of Fe because they generally proliferate at 
a higher rate than their normal counterparts (39,40). This is 
reflected by the upregulated expression of the transferrin 
receptor protein 1 (TfR1) (41) and the higher rate of Fe uptake 
from transferrin (Tf) in cancer cells (42,43). Furthermore, 
neoplastic cells express high levels of ribonucleotide reductase 
(RR) (44,45), rendering them more susceptible to Fe chela-
tors than normal cells (39,46). Early studies showed that the 
clinically utilized Fe chelator, deferoxamine (DFO), exerts 
some inhibitory effects on the growth of neuroblastoma and 
leukemia cells in culture and in clinical trials (47-51).
One mechanism by which Fe chelators exert anti-prolifer-
ative effects on tumors is through targeting molecules that are 
critical for regulating cell cycle progression (52,53).
Importantly, the effects of Fe chelators on CCND1 
expression were determined to be due to Fe depletion, as Fe 
supplementation reversed these effects (20).
Furthermore, Fe depletion appears to have similar effects 
on both CCND1 and p21CIP1/WAF1 protein expression: 
it induces the ubiquitin-independent degradation of these 
proteins (20,54).
Figure 4. Comparison of the antitumor effect of DFO and eltrombopag (EP). 
Huh7 cells were treated with 0.1-100 µg/ml of DFO for 72 h, or not treated. 
Cell viability was measured by a CCK-8 assay performed at 72 h. *P<0.05 
compared to the same concentration of EP. The values indicate a ratio com-
pared to 0 µg/ml DFO as 100% control.
Figure 5. Combined effects of eltrombopag (EP) and sorafenib on HCC. 
(A) Huh7 cells were treated with 0.1-100 µg/ml of EP and sorafenib (0 and 
4 µM), or not treated. *P<0.05 compared to 0 µg/ml EP and 4 µM sorafenib. 
The values indicate a ratio compared to 0 µg/ml EP and 4 µM sorafenib 
as 100% control. (B) Combination index values were determined using the 
method described by Chou (19); CI=1, cumulative effect; CI<1, synergistic 
effect; and CI>1, antagonistic effect.
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The following important findings were also obtained via 
our experiments.
In addition to DFO, the most common iron chelator (55), 
which is used in the clinic, recent studies have characterized 
new iron chelators, such as deferasirox, Dp44mT (56) and 
O-Trensox (57). These iron chelators induce growth inhibition 
in breast cancer cells and neuroblastoma (37,58). Although 
DFO, which exhibited a similar antitumor effect as EP in 
our study, is commonly used in patients, its poor membrane 
permeability and inability to permit redox cycling of iron 
are disadvantageous in terms of eliciting an anti-proliferative 
effect (55). Additionally, DFO is poorly absorbed in the intes-
tine, and it must be administered via an intravenous route; 
furthermore, DFO has a very short plasma half-life (55). These 
disadvantages prompted the search for more effective chela-
tors that are easier to administer to patients. From the results 
of our study, EP would be a candidate for drug as effective 
chelator in a clinical study.
It is well known that patients with the congenital iron 
overload disease hemochromatosis are more likely to develop 
HCC compared with the general population (2). A review 
by Gangaidzo and Gordeuk suggest that iron overload may 
contribute to the high incidence of HCC in Africa (59).
Furthermore, iron chelators have been reported to be useful 
for HCC treatment in vitro, in vivo and in the clinic (57,60,61).
Iron reduction therapy, such as phlebotomy or a low iron 
diet, is used to improve liver function and to prevent carcino-
genesis in patients with chronic hepatitis C (62,63).
Conversely, it has been reported that the iron chelator 
DFO protects against the cytotoxic effects of sorafenib in 
HCC cells (64). The findings suggest that sorafenib can induce 
ferroptosis, which is a novel form of programmed cell death.
Thus, a potential method to attenuate the effects of 
sorafenib is to reduce intracellular iron levels. The cytotoxic 
effect of sorafenib is markedly offset when the concentration 
of EP increases, which is consistent with our results (Fig. 5).
Drug repositioning, in which existing drugs are used for 
new purposes, is a cost-effective strategy for identifying new 
treatments for existing conditions, and finding use for drugs 
for which development has ceased; this strategy has been used 
to identify new usage for several drugs, including thalidomide 
and plerixafor (65,66). In recent years, significant progress 
in drug discovery technology and bioinformatics has facili-
tated drug repositioning, and new drug discovery tools are 
eliminating the innovation gap (67). This study identified EP 
as a candidate for drug repositioning efforts, which should 
lead to the novel clinical use of EP in patients with HCC and 
LC (Fig. 6).
EP interacts with the transmembrane domain of TPO-R. 
This interaction and subsequent TPO-R downstream signaling 
is highly species-specific and occurs only in humans and 
primates, not in murine cells (68).
Therefore, it is difficult to conduct an in vivo study on EP, 
and the lack of in vivo data represents a limitation of this study.
However, short-term EP treatment is useful and safe in 
combination with radio-frequency ablation in HCC patients 
with LC and severe thrombocytopenia, as the risk of bleeding 
is mitigated by the increase in platelets (69); moreover, EP 
does not have a proliferative effect on HCC (69). This option 
should be considered in clinical trials.
In conclusion, the present study demonstrated that EP is a 
promising and safe chemotherapeutic agent for the treatment 
of HCC in patients with LC and thrombocytopenia.
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